Treatment of Graves’ Orbitopathy with Sight-Threatening Thyroid Eye Disease and Dysthyroid Optic Neuropathy
Clinical Scenario
This protocol targets Graves’ orbitopathy at its most urgent presentation: sight-threatening thyroid eye disease in the form of dysthyroid optic neuropathy (DON). In this setting, enlarged extraocular muscles at the orbital apex compress the optic nerve, placing visual function in immediate jeopardy.
Condition Detail
DON may result from compression of the optic nerve by enlarged extraocular muscles at the apex of the orbit, or infrequently (<5%), from stretch of the nerve due to proptosis. It can co-occur with corneal breakdown or globe subluxation, each of which constitutes a sight-threatening complication requiring prompt assessment.
Treatment Approach (Partial Overview)
Management requires urgent intravenous glucocorticoid (IVGC) therapy, administered with close monitoring of the clinical response. This is not a wait-and-watch scenario — the treatment window is narrow and structured.
The primary treatment targets are:
- Visual recovery with improvement in visual acuity
- Visual function must not deteriorate at two weeks
The complete regimen — including dosing schedule, monitoring criteria, and escalation pathway — is available in the full structured protocol below.
References
doi: 10.1089/thy.2022.0251
- Patients with DON and/or corneal breakdown and/or globe subluxation require urgent management.
- DON may result from compression of the optic nerve by enlarged EOM at the apex of the orbit, or infrequently (<5%), due to stretch of the nerve because of proptosis.
- Patients with DON require urgent treatment with IVGC therapy, with close monitoring of response and early (after two weeks) consideration for decompression surgery if baseline visual function is not restored and maintained with medical therapy.
- Although the optimal dose and schedule of GC are not established, the recommended use of large doses of IVMP daily for 3 consecutive or alternate days is based on the experience of treating patients with optic neuritis from other etiologies.
- IVGC has been reported to be effective in approximately 40% of DON patients, generating improvements in visual acuity and avoiding subsequent orbital decompression.
- Visual deterioration 2 weeks after initiating therapy is also predictive of poor response to IVGC.
View source ↗